Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 14:
15. A method for treatment of cancer, wherein said method comprises administering, to a subject in need thereof, a pharmaceutically active amount of at least one polypeptide, wherein the polypeptide comprises at least one immunoglobulin single variable domain (ISVD) that specifically binds glucocorticoid-induced TNFR family-related receptor (GITR) with an EC50 value of less than 200 pM, wherein the binding of said ISVD to said GITR enhances an immune response, and wherein said at least one immunoglobulin single variable domain essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
(i) CDR1 is chosen from the group consisting of:
(a) SEQ ID NOs: 73-88; and
(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequences of SEQ ID NOs: 73-88; and/or

(ii) CDR2 is chosen from the group consisting of:
(c) SEQ ID NOs: 90-116; and
(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequences of SEQ ID NOs: 90-116; and/or

(iii) CDR3 is chosen from the group consisting of:
(e) SEQ ID NOs: 118-132 and 282-284; and
(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequences of SEQ ID NOs: 118-132 and 282-284.